Plate-based diversity subset screening generation 2: an improved paradigm for high-throughput screening of large compound files

被引:0
作者
Andrew S. Bell
Joseph Bradley
Jeremy R. Everett
Jens Loesel
David McLoughlin
James Mills
Marie-Claire Peakman
Robert E. Sharp
Christine Williams
Hongyao Zhu
机构
[1] Pfizer Worldwide Research and Development,Scitegrity Ltd
[2] Pfizer Worldwide Research & Development,undefined
[3] Imperial College,undefined
[4] Discovery Park,undefined
[5] University of Greenwich,undefined
[6] JL Consulting,undefined
[7] Eli Lilly & Company,undefined
[8] Sandexis Medicinal Chemistry Ltd,undefined
[9] RES Consulting,undefined
[10] Ipsen,undefined
来源
Molecular Diversity | 2016年 / 20卷
关键词
Rule of 40; Ro40; High-throughput screening (HTS); Plate-based; Diversity; Subset; Screening file; 2nd Generation; Lead discovery;
D O I
暂无
中图分类号
学科分类号
摘要
High-throughput screening (HTS) is an effective method for lead and probe discovery that is widely used in industry and academia to identify novel chemical matter and to initiate the drug discovery process. However, HTS can be time consuming and costly and the use of subsets as an efficient alternative to screening entire compound collections has been investigated. Subsets may be selected on the basis of chemical diversity, molecular properties, biological activity diversity or biological target focus. Previously, we described a novel form of subset screening: plate-based diversity subset (PBDS) screening, in which the screening subset is constructed by plate selection (rather than individual compound cherry-picking), using algorithms that select for compound quality and chemical diversity on a plate basis. In this paper, we describe a second-generation approach to the construction of an updated subset: PBDS2, using both plate and individual compound selection, that has an improved coverage of the chemical space of the screening file, whilst only selecting the same number of plates for screening. We describe the validation of PBDS2 and its successful use in hit and lead discovery. PBDS2 screening became the default mode of singleton (one compound per well) HTS for lead discovery in Pfizer.
引用
收藏
页码:789 / 803
页数:14
相关论文
共 231 条
  • [1] Scannell JW(2012)Diagnosing the decline in pharmaceutical R&D efficiency Nat Rev Drug Discov 11 191-200
  • [2] Blanckley A(2011)The impact of mergers on pharmaceutical R&D Nat Rev Drug Discov 10 559-560
  • [3] Boldon H(2010)How to improve R&D productivity: the pharmaceutical industry’s grand challenge Nat Rev Drug Discov 9 203-214
  • [4] Warrington B(2011)The productivity crisis in pharmaceutical R&D Nat Rev Drug Discov 10 428-438
  • [5] LaMattina JL(2014)Improving productivity of modern-day drug discovery Expert Opin Drug Dis 9 115-118
  • [6] Paul SM(2013)Design principles for innovative workspaces to increase efficiency in pharmaceutical R&D: lessons learned from the Novartis campus Drug Discov Today 18 318-322
  • [7] Mytelka DS(2013)Is poor research the cause of the declining productivity of the pharmaceutical industry? An industry in need of a paradigm shift Drug Discov Today 18 211-217
  • [8] Dunwiddie CT(2014)Quantitative systems pharmacology can reduce attrition and improve productivity in pharmaceutical research and development Front Pharmacol 5 247-527
  • [9] Persinger CC(2014)The paradox of scientific excellence and the search for productivity in pharmaceutical research and development Clin Pharmacol Ther 95 521-527
  • [10] Munos BH(2014)Potential strategies for increasing drug-discovery productivity Future Med Chem 6 515-871